BackCytoMed Therapeutics Overview

CytoMed Therapeutics Receivables

Track CytoMed Therapeutics's receivables ($130K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$132054.00
↑ 18.78% YoYΔ $20880.00 vs prior year quarter

Peer average

Loading

CytoMed Therapeutics Receivables History

Loading

CytoMed Therapeutics vs. peers: Receivables Comparison

Loading

CytoMed Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytoMed Therapeutics (GDTC) FAQ

As of the most recent data (December 2025), GDTC shows a receivables of $130K. That compares with $110K in the prior-year period — up 18.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GDTC's receivables is now $130K (was $110K) — a 18.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether CytoMed Therapeutics is outperforming or lagging.

Tracking GDTC's receivables over time shows whether CytoMed Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $130K That compares with $110K in the prior-year period — up 18.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has CytoMed Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $130K) with ownership activity and broader fundamentals.